nach oben

Digestive Diseases and Sciences

Erschienen in:

17.05.2022 | Editorial

MAFLD Versus NAFLD: Which Better Predicts the Risk of Atherosclerotic Cardiovascular Disease?

verfasst von: Andrew R. Scheinberg, Binu V. John

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Excerpt

Non-alcoholic fatty liver disease (NAFLD) is a progressive chronic liver disease that if untreated may progress to cirrhosis and the development of its complications including hepatocellular carcinoma (HCC) [1]. With the successful and widely-available treatment of hepatitis C virus (HCV) infection globally combined with an unfortunate booming obesity epidemic, NAFLD has emerged as the leading cause of end-stage liver disease. …

Li B, Zhang C, Zhan YT. nonalcoholic fatty liver disease cirrhosis: a review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis. Can J Gastroenterol Hepatol 2018;2018:2784537.CrossRef

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology 2018;67(1):328–357.CrossRef

Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999–2014.e1.CrossRef

Kim H. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci. (Epub ahead of print). https://doi.org/10.1007/s10620-022-07508-6.

Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol 2021;19:2172–2181.CrossRef

Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol 2021;75:1284–1291.CrossRef

Kim D, Ahmed A. Reply to: “NAFLD vs MAFLD - It is not the name but the disease that decides the outcome in fatty liver.” J Hepatol. 2022;76:477–478.CrossRef

Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, Yong JN, Xiao J, Lee CW, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.11.038.CrossRefPubMed

Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40:3018–3030.CrossRef

10.

Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. MAFLD and risk of CKD. Metabolism. 2021;115:154433.CrossRef

Titel: MAFLD Versus NAFLD: Which Better Predicts the Risk of Atherosclerotic Cardiovascular Disease?
verfasst von: Andrew R. Scheinberg
Binu V. John
Publikationsdatum: 17.05.2022
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 10/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-022-07512-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

MAFLD Versus NAFLD: Which Better Predicts the Risk of Atherosclerotic Cardiovascular Disease?

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

COVID-19 Vaccine Hesitancy in Patients with Inflammatory Bowel Disease

Gastrointestinal Infections and the Risk of Inflammatory Bowel Disease in Twins and Siblings: Evidence Against the Hygiene Hypothesis

Benefit of Antiviral Therapy for HBV-Related HCC with Undetectable HBV DNA Is Still Dubious

It’s Not What You Take Up, It’s What You Keep: How Discoveries from Diverse Disciplines Directed the Development of the FDG PET/CT Scan

Aspartate Aminotransferase-to-Platelet Ratio Index Predicts Liver Failure After Resection of Colorectal Liver Metastases

Advanced Endoscopic Resection Techniques in Cirrhosis—A Systematic Review and Meta-Analysis of Outcomes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin